Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Biodistribution and radiation dosimetry of the 18 kDa translocator protein (TSPO) radioligand [18F]FEDAA1106: a human whole-body PET study.
Takano A, Gulyás B, Varrone A, Karlsson P, Sjoholm N, Larsson S, Jonsson C, Odh R, Sparks R, Al Tawil N, Hoffmann A, Zimmermann T, Thiele A, Halldin C. Takano A, et al. Among authors: al tawil n. Eur J Nucl Med Mol Imaging. 2011 Nov;38(11):2058-65. doi: 10.1007/s00259-011-1864-3. Epub 2011 Jul 6. Eur J Nucl Med Mol Imaging. 2011. PMID: 21732107 Clinical Trial.
In vivo imaging of the 18-kDa translocator protein (TSPO) with [18F]FEDAA1106 and PET does not show increased binding in Alzheimer's disease patients.
Varrone A, Mattsson P, Forsberg A, Takano A, Nag S, Gulyás B, Borg J, Boellaard R, Al-Tawil N, Eriksdotter M, Zimmermann T, Schultze-Mosgau M, Thiele A, Hoffmann A, Lammertsma AA, Halldin C. Varrone A, et al. Among authors: al tawil n. Eur J Nucl Med Mol Imaging. 2013 Jun;40(6):921-31. doi: 10.1007/s00259-013-2359-1. Epub 2013 Feb 22. Eur J Nucl Med Mol Imaging. 2013. PMID: 23436070
Positron emission tomography imaging of the 18-kDa translocator protein (TSPO) with [18F]FEMPA in Alzheimer's disease patients and control subjects.
Varrone A, Oikonen V, Forsberg A, Joutsa J, Takano A, Solin O, Haaparanta-Solin M, Nag S, Nakao R, Al-Tawil N, Wells LA, Rabiner EA, Valencia R, Schultze-Mosgau M, Thiele A, Vollmer S, Dyrks T, Lehmann L, Heinrich T, Hoffmann A, Nordberg A, Halldin C, Rinne JO. Varrone A, et al. Among authors: al tawil n. Eur J Nucl Med Mol Imaging. 2015 Mar;42(3):438-46. doi: 10.1007/s00259-014-2955-8. Epub 2014 Nov 21. Eur J Nucl Med Mol Imaging. 2015. PMID: 25412766 Clinical Trial.
Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer's disease and elderly controls after oral administration of sembragiline.
Sturm S, Forsberg A, Nave S, Stenkrona P, Seneca N, Varrone A, Comley RA, Fazio P, Jamois C, Nakao R, Ejduk Z, Al-Tawil N, Akenine U, Halldin C, Andreasen N, Ricci B. Sturm S, et al. Among authors: al tawil n. Eur J Nucl Med Mol Imaging. 2017 Mar;44(3):382-391. doi: 10.1007/s00259-016-3510-6. Epub 2016 Sep 16. Eur J Nucl Med Mol Imaging. 2017. PMID: 27633250 Free PMC article. Clinical Trial.
In vivo measurement of PDE10A enzyme occupancy by positron emission tomography (PET) following single oral dose administration of PF-02545920 in healthy male subjects.
Delnomdedieu M, Forsberg A, Ogden A, Fazio P, Yu CR, Stenkrona P, Duvvuri S, David W, Al-Tawil N, Vitolo OV, Amini N, Nag S, Halldin C, Varrone A. Delnomdedieu M, et al. Among authors: al tawil n. Neuropharmacology. 2017 May 1;117:171-181. doi: 10.1016/j.neuropharm.2017.01.016. Epub 2017 Jan 22. Neuropharmacology. 2017. PMID: 28122201
Patterns of age related changes for phosphodiesterase type-10A in comparison with dopamine D2/3 receptors and sub-cortical volumes in the human basal ganglia: A PET study with 18F-MNI-659 and 11C-raclopride with correction for partial volume effect.
Fazio P, Schain M, Mrzljak L, Amini N, Nag S, Al-Tawil N, Fitzer-Attas CJ, Bronzova J, Landwehrmeyer B, Sampaio C, Halldin C, Varrone A. Fazio P, et al. Among authors: al tawil n. Neuroimage. 2017 May 15;152:330-339. doi: 10.1016/j.neuroimage.2017.02.047. Epub 2017 Feb 28. Neuroimage. 2017. PMID: 28254508
PET Molecular Imaging of Phosphodiesterase 10A: An Early Biomarker of Huntington's Disease Progression.
Fazio P, Fitzer-Attas CJ, Mrzljak L, Bronzova J, Nag S, Warner JH, Landwehrmeyer B, Al-Tawil N, Halldin C, Forsberg A, Ware J, Dilda V, Wood A, Sampaio C, Varrone A; PEARL-HD and LONGPDE10 study collaborators. Fazio P, et al. Among authors: al tawil n. Mov Disord. 2020 Apr;35(4):606-615. doi: 10.1002/mds.27963. Epub 2020 Jan 22. Mov Disord. 2020. PMID: 31967355
Pharmacokinetics of transdermal buprenorphine patch in the elderly.
Al-Tawil N, Odar-Cederlöf I, Berggren AC, Johnson HE, Persson J. Al-Tawil N, et al. Eur J Clin Pharmacol. 2013 Feb;69(2):143-9. doi: 10.1007/s00228-012-1320-8. Epub 2012 Jun 17. Eur J Clin Pharmacol. 2013. PMID: 22706617 Free PMC article. Clinical Trial.
Evaluation of safety and efficacy as an adjuvant for the chitosan-based vaccine delivery vehicle ViscoGel in a single-blind randomised Phase I/IIa clinical trial.
Neimert-Andersson T, Binnmyr J, Enoksson M, Langebäck J, Zettergren L, Hällgren AC, Franzén H, Lind Enoksson S, Lafolie P, Lindberg A, Al-Tawil N, Andersson M, Singer P, Grönlund H, Gafvelin G. Neimert-Andersson T, et al. Among authors: al tawil n. Vaccine. 2014 Oct 14;32(45):5967-74. doi: 10.1016/j.vaccine.2014.08.057. Epub 2014 Sep 16. Vaccine. 2014. PMID: 25218298 Clinical Trial.
66 results